Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopust… Read more
Sol Gel Technologies Ltd (SLGL) - Net Assets
Latest net assets as of September 2025: $26.03 Million USD
Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) has net assets worth $26.03 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.59 Million) and total liabilities ($8.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.03 Million |
| % of Total Assets | 75.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | -43.26% |
| 10-Year Change | N/A |
| Growth Volatility | 12.28 |
Sol Gel Technologies Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Sol Gel Technologies Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sol Gel Technologies Ltd (2014–2024)
The table below shows the annual net assets of Sol Gel Technologies Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $28.85 Million | -25.34% |
| 2023-12-31 | $38.64 Million | -8.45% |
| 2022-12-31 | $42.21 Million | -24.07% |
| 2021-12-31 | $55.59 Million | +9.33% |
| 2020-12-31 | $50.85 Million | -3.08% |
| 2019-12-31 | $52.47 Million | -17.91% |
| 2018-12-31 | $63.91 Million | +221.27% |
| 2017-12-31 | $-52.70 Million | -68.17% |
| 2016-12-31 | $-31.34 Million | -172.07% |
| 2015-12-31 | $-11.52 Million | -406.29% |
| 2014-12-31 | $-2.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sol Gel Technologies Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19762100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $774.00K | 2.68% |
| Other Components | $258.96 Million | 897.60% |
| Total Equity | $28.85 Million | 100.00% |
Sol Gel Technologies Ltd Competitors by Market Cap
The table below lists competitors of Sol Gel Technologies Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PRL Global Ltd
AU:PRG
|
$43.86 Million |
|
Tifico Fiber Indonesia Tbk
JK:TFCO
|
$43.87 Million |
|
SomnoMed Limited
PINK:SOMNF
|
$43.88 Million |
|
FIRST TIN PLC LS-001
F:1SN
|
$43.89 Million |
|
QS Energy Inc
PINK:QSEP
|
$43.86 Million |
|
Telesat Corp
NASDAQ:TSAT
|
$43.85 Million |
|
RAMADA INV.E IND.NAM.EO 1
F:Y4E
|
$43.84 Million |
|
Hinduja Global Solutions Limited
NSE:HGS
|
$43.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sol Gel Technologies Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 38,644,000 to 28,850,000, a change of -9,794,000 (-25.3%).
- Net loss of 10,580,000 reduced equity.
- Other factors increased equity by 786,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.58 Million | -36.67% |
| Other Changes | $786.00K | +2.72% |
| Total Change | $- | -25.34% |
Book Value vs Market Value Analysis
This analysis compares Sol Gel Technologies Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 77.00x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-1.11 | $79.75 | x |
| 2015-12-31 | $-0.98 | $79.75 | x |
| 2016-12-31 | $-2.67 | $79.75 | x |
| 2017-12-31 | $-2.93 | $79.75 | x |
| 2018-12-31 | $3.58 | $79.75 | x |
| 2019-12-31 | $2.69 | $79.75 | x |
| 2020-12-31 | $2.25 | $79.75 | x |
| 2021-12-31 | $2.36 | $79.75 | x |
| 2022-12-31 | $1.83 | $79.75 | x |
| 2023-12-31 | $1.43 | $79.75 | x |
| 2024-12-31 | $1.04 | $79.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sol Gel Technologies Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -36.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -91.70%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.24x
- Recent ROE (-36.67%) is below the historical average (-26.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.55 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.51 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.64 Million |
| 2017 | 0.00% | -18142.53% | 0.01x | 0.00x | $-26.30 Million |
| 2018 | -50.39% | -24963.57% | 0.00x | 1.09x | $-38.59 Million |
| 2019 | -46.91% | -107.44% | 0.37x | 1.17x | $-29.86 Million |
| 2020 | -53.89% | -312.40% | 0.15x | 1.16x | $-32.49 Million |
| 2021 | 5.79% | 10.30% | 0.45x | 1.24x | $-2.34 Million |
| 2022 | -35.35% | -384.32% | 0.08x | 1.10x | $-19.14 Million |
| 2023 | -70.48% | -1752.77% | 0.03x | 1.17x | $-31.10 Million |
| 2024 | -36.67% | -91.70% | 0.32x | 1.24x | $-13.46 Million |
Industry Comparison
This section compares Sol Gel Technologies Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sol Gel Technologies Ltd (SLGL) | $26.03 Million | 0.00% | 0.33x | $43.86 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |